Alexion Pharmaceuticals

Contact Us Legal Sitemap

Prevalence

PNH is a rare blood disorder that affects an estimated 8,000 to 10,000 people in North America and Europe and, potentially 1,000 to 2,000 patients in Japan based on a study designed to look at PNH prevalence.10 Due to the rareness of PNH, its global impact is not fully known.

PNH can affect men and women of all races and ages, but it is most commonly diagnosed between the ages of 20 to 40 years old.11-13 Following diagnosis, the median survival for PNH, if untreated, is approximately 10 to 15 years.3,12 Although PNH is rare, the medical community continues to learn more about the disease as new study results are presented.



IMPORTANT SAFETY INFORMATION

Soliris increases the risk of meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early

Soliris® increases the risk of meningococcal infections

  • Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use
  • Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary

The effect of anticoagulant withdrawal during Soliris treatment has not been studied. Therefore, treatment with Soliris should not alter anticoagulant management.

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, a runny nose (nasopharyngitis), back pain, nausea, and tiredness (fatigue).

Please see full Prescribing Information and Important Safety Information for Soliris® (eculizumab).